Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03590652

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma Clinical Trial

Official title:
Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma A University of California Hematologic Malignancies Consortium Protocol (UCHMC1809)

Clinical Trial Summary

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.

Clinical Trial Description

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone. The drugs being used in this study are daratumumab ixazomib, pomalidomide, and dexamethasone. Ixazomib may stop the growth of cancer by interfering with proteasomes (the protein breakdown mechanism in the cells). Pomalidomide, and dexamethasone are standard drugs that can change and regulate the immune system and may stop cancer cells from growing. Both Ixazomib and Daratumumab are approved for use in Multiple Myeloma, but not in this combination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03590652
Study type Interventional
Source University of California, San Diego
Contact
Status Active, not recruiting
Phase Phase 2
Start date October 17, 2018
Completion date October 1, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05427812 - Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma Phase 1/Phase 2
Active, not recruiting NCT04093596 - Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) Phase 1
Not yet recruiting NCT05498545 - Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Recruiting NCT04973605 - A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05376345 - BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Withdrawn NCT05980507 - An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma Phase 1
Active, not recruiting NCT04601935 - A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma Phase 1
Terminated NCT06160609 - Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM Phase 1/Phase 2
Completed NCT03309111 - Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Phase 1
Recruiting NCT06049290 - A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05259839 - A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma Phase 1
Terminated NCT03318861 - Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma Phase 1
Completed NCT01794520 - Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT04142619 - Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) Phase 1
Completed NCT01849848 - Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma Phase 2
Completed NCT01794507 - A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Phase 1
Recruiting NCT05160584 - A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Terminated NCT03287908 - A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Phase 1
Recruiting NCT05862012 - Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma Phase 1
Completed NCT03489525 - MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma Phase 1